Atlas Venture Opportunity Fund I, L.P.'s Net Worth
$59.8 Million
Who is Atlas Venture Opportunity Fund I, L.P.?
Atlas Venture Opportunity Fund I, L.P. has an estimated net worth of $59.8 Million. This is based on reported shares across multiple companies, which include Vigil Neuroscience, Inc., Day One Biopharmaceuticals, Inc., Dyne Therapeutics, Inc., Generation Bio Co., Akero Therapeutics, Inc., Replimune Group, Inc., Ikena Oncology, Inc., Kymera Therapeutics, Inc., Magenta Therapeutics, Inc., Disc Medicine, Inc., Xilio Therapeutics, Inc., AVROBIO, Inc., Third Harmonic Bio, Inc., and Homology Medicines, Inc..
SEC CIK
Atlas Venture Opportunity Fund I, L.P.'s CIK is 0001759241
Past Insider Trading and Trends
2022 was Atlas Venture Opportunity Fund I, L.P.'s most active year for disposing of shares, totalling 1 transactions. Atlas Venture Opportunity Fund I, L.P.'s most active month to dispose stocks was the month of February. In 2024 Atlas Venture Opportunity Fund I, L.P. cashed out on 29,435 shares for a total of $884,521.75, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Day One Biopharmaceuticals, Inc. (DAWN) Snapshot price: $13.5
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -20.00% | -198.28K |
—
|
—
| 793.12K |
Scheduled
|
Jul 1
| ||
Form 4
|
∞
| 766.67K |
$15.00 | $11,500,005.00 | 766.67K |
Jun 17
| |||
Form 4
|
∞
| 9M |
$16.00 | $8,000,000.00 | 9M |
Feb 1 - Jun 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Dyne Therapeutics, Inc. (DYN) Snapshot price: $33.03
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -1.98% | -46.53K |
$30.05 | -$1,398,346.70 | 2.31M |
Scheduled
|
Mar 1
| ||
Form 4
| -5.89% | -807.84K |
$24.32 | -$19,626,902.97 | 12.9M |
Scheduled
|
Feb 26 - Feb 28
| ||
Form 4
| -5.35% | -500.79K |
$22.68 | -$11,339,780.44 | 8.86M |
Scheduled
|
Feb 21 - Feb 23
| ||
Form 4
|
∞
| 934.58K |
$10.70 | $10,000,016.70 | 934.58K |
Dec 12
| |||
Form 4
| +361.95% | 7.64M |
—
|
—
| 9.75M |
Sep 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Akero Therapeutics, Inc. (AKRO) Snapshot price: $26.41
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -11.11% | -50.51K |
—
|
—
| 404.08K |
Scheduled
|
Feb 7
| ||
Form 4
| -14.36% | -570.97K |
—
|
—
| 3.4M |
Scheduled
|
Dec 17
| ||
Form 4
|
∞
| 3.97M |
$16.00 |
—
| 3.97M |
Jun 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Ikena Oncology, Inc. (IKNA) Snapshot price: $1.77
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +4.89% | 98.72K |
$15.34 | $1,614,428.13 | 2.12M |
Mar 30 - Dec 14
| |||
Form 4
| +2,809.29% | 4.75M |
—
|
—
| 4.92M |
Mar 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Xilio Therapeutics, Inc. (XLO) Snapshot price: $0.844
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -0.04% | -1.00K |
$0.64 | -$640.00 | 2.75M |
Feb 8
| |||
Form 4
| -0.15% | -4.24K |
$0.85 | -$3,600.45 | 2.76M |
Jan 11 - Jan 12
| |||
Form 4
| +10,385.82% | 2.73M |
$16.00 |
—
| 2.76M |
Oct 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||